Abstract:Drug resistance significantly impairs the efficacy of AIDS therapy. Therefore, precise prediction of resistant viral mutants is particularly useful for developing effective drugs and designing therapeutic regimen. In this study, we applied a structure‐based computational approach to predict mutants of the HIV‐1 protease resistant to the seven FDA approved drugs. We analyzed the energetic pattern of the protease‐drug interaction by calculating the molecular interaction energy components (MIECs) between the drug and the protease residues. Support vector machines (SVMs) were trained on MIECs to classify protease mutants into resistant and nonresistant categories. The high prediction accuracies for the test sets of cross‐validations suggested that the MIECs successfully characterized the interaction interface between drugs and the HIV‐1 protease. We conducted a proof‐of‐concept study on a newly approved drug, darunavir (TMC114), on which no drug resistance data were available in the public domain. Compared with amprenavir, our analysis suggested that darunavir might be more potent to combat drug resistance. To quantitatively estimate binding affinities of drugs and study the contributions of protease residues to causing resistance, linear regression models were trained on MIECs using partial least squares (PLS). The MIEC‐PLS models also achieved satisfactory prediction accuracy. Analysis of the fitting coefficients of MIECs in the regression model revealed the important resistance mutations and shed light into understanding the mechanisms of these mutations to cause resistance. Our study demonstrated the advantages of characterizing the protease‐drug interaction using MIECs. We believe that MIEC‐SVM and MIEC‐PLS can help design new agents or combination of therapeutic regimens to counter HIV‐1 protease resistant strains. Proteins 2009. © 2008 Wiley‐Liss, Inc.

Proteochemometric Modeling Of The Bioactivity Spectra Of Hiv-1 Protease Inhibitors By Introducing Protein-Ligand Interaction Fingerprint

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Revealing the Mutation Patterns of Drug-Resistant Reverse Transcriptase Variants of Human Immunodeficiency Virus through Proteochemometric Modeling

Modeling Studies of Peptide Inhibitors for the HIV Protease

Constructing Interconsistent, Reasonable, and Predictive Models for Both the Kinetic and Thermodynamic Properties of HIV-1 Protease Inhibitors.

Quantitatives Structure-Activity Relationship and Modification of HIV Protease Inhibitors

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Elucidating the Inhibiting Mode of AHPBA Derivatives Against HIV-1 Protease and Building Predictive 3D-QSAR Models

Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

Computational Studies on Tetrahydropyrimidine-2-one HIV-1 Protease Inhibitors: Improving Three-Dimensional Quantitative Structure-Activity Relationship Comparative Molecular Field Analysis Models by Inclusion of Calculated Inhibitor- and Receptor-Based Properties.

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods

Predicting Drug Resistance of the HIV‐1 Protease Using Molecular Interaction Energy Components

Prediction of viral protease inhibitors using proteochemometrics approach

Identifying the Molecular Mechanics and Binding Dynamics Characteristics of Potent Inhibitors to HIV‐1 Protease

Identifying Chemicals With Potential Therapy Of Hiv Based On Protein-Protein And Protein-Chemical Interaction Network

Studies of Relationship Between Biological Activities and HIV Reverse Transcriptase Inhibitors by Multivariate Adaptive Regression Splines with Curds and Whey

Study on human GPCR-inhibitor interactions by proteochemometric modeling.

Accurate Prediction of Relative Binding Affinities of a Series of HIV-1 Protease Inhibitors Using Semi-Empirical Quantum Mechanical Charge

Screening of Selective Histone Deacetylase Inhibitors by Proteochemometric Modeling